PXL770

DRUG5 trials

Sponsors

Poxel SA

Conditions

AdrenomyeloneuropathyMetabolic DiseaseNASH - Nonalcoholic SteatohepatitisNonalcoholic Fatty Liver

Phase 1

Safety, Tolerability and PK of PXL770 in Healthy Male Subjects

CompletedNCT03395470

Poxel SAMetabolic Disease

Start: 2017-08-21End: 2018-03-16Updated: 2018-08-24

A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD

CompletedNCT03950882

Poxel SANonalcoholic Fatty Liver

Start: 2019-08-01End: 2020-03-31Updated: 2021-06-11

Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects.

CompletedNCT05441904

Poxel SANASH - Nonalcoholic Steatohepatitis

Start: 2021-03-08End: 2021-03-29Updated: 2022-07-01

Phase 2

A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD

CompletedNCT03763877

Poxel SANonalcoholic Fatty Liver

Start: 2019-03-29End: 2020-08-10Updated: 2021-10-28

Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)

WithdrawnNCT05146284

Poxel SAAdrenomyeloneuropathy

Start: 2023-09-30End: 2024-09-30Updated: 2024-12-16

Related Papers

Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.

2021-09-2253 citations